Skip to content
HowShorted

RIGEL PHARMACEUTICALS INC short interest in 2021

In 2021, RIGEL PHARMACEUTICALS INC's disclosed short interest ran from 12.64% of shares outstanding on 15 Jan 2021 to 8.63% on 31 Dec 2021, a change of -4.01 percentage points. The year's high was 14.27% on 15 Jun 2021 and its low 8.63% on 31 Dec 2021, averaging 11.50% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 21.26 days on 30 Jul 2021. Full history: RIGEL PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for RIGEL PHARMACEUTICALS INC in 2021

2021 in figures

Start of year
12.64% (15 Jan 2021)
End of year
8.63% (31 Dec 2021)
Change
-4.01 pp
High
14.27% (15 Jun 2021)
Low
8.63% (31 Dec 2021)
Average
11.50%
Highest days to cover
21.26 (30 Jul 2021)
SEC filings marked
9

Every report in 2021

RIGEL PHARMACEUTICALS INC short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202112.64%10.36results (8-K)
29 Jan 202112.41%8.20
12 Feb 202111.46%5.16
26 Feb 20219.95%2.67
15 Mar 20219.98%4.7110-K filed, results (8-K)
31 Mar 202113.04%9.11
15 Apr 202113.81%5.92
30 Apr 202113.21%10.37
14 May 202114.06%7.7510-Q filed, results (8-K)
28 May 202113.79%19.03
15 Jun 202114.27%9.92
30 Jun 202112.69%10.23
15 Jul 202112.24%18.89
30 Jul 202112.13%21.26
13 Aug 202112.16%7.7010-Q filed, results (8-K)
31 Aug 202111.36%17.40
15 Sep 202110.92%12.83
30 Sep 202110.04%12.85
15 Oct 202110.03%17.70
29 Oct 202110.04%18.70
15 Nov 20219.42%10.9010-Q filed, results (8-K)
30 Nov 20218.81%6.55
15 Dec 20219.00%9.60
31 Dec 20218.63%9.11

See also: RIGEL PHARMACEUTICALS INC's full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.